Biodexa Pharmaceuticals Plc American Depositary Receipt(BDRX US)
$3.69+0.308.97%
Get the full experience
We save the real magic for signed-in users.
| Millions GBP (ex. Per Share) | FY201212/31/2012 | FY201312/31/2013 | FY201412/31/2014 | FY201512/31/2015 | FY201612/31/2016 | FY201712/31/2017 | FY201812/31/2018 | FY201912/31/2019 | FY202012/31/2020 | FY202112/31/2021 | FY202212/31/2022 | FY202312/31/2023 | FY202412/31/2024 | FY202512/31/2025 | Last 12M06/30/2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | 6.0 | 1.7 | 8.5 | 3.2 | |||||||||||||
| Short Term Investments | - | - | - | - | |||||||||||||
| Cash and Short Term Investments | 6.0 | 1.7 | 8.5 | 3.2 | |||||||||||||
| Net Receivables | 0.7 | 0.7 | 0.2 | 3.4 | |||||||||||||
| Inventory | -0.7 | - | - | - | |||||||||||||
| Other Current Assets | 0.7 | - | - | - | |||||||||||||
| Total Current Assets | 7.0 | 8.8 | 12.4 | 6.6 | |||||||||||||
| Property, Plant & Equipment | 0.6 | 0.3 | 0.1 | 0.0 | |||||||||||||
| Long Term Investments | - | - | - | - | |||||||||||||
| Other Non-Current Assets | - | - | - | - | |||||||||||||
| Total Non-Current Assets | 3.5 | 6.0 | 5.7 | 6.0 | |||||||||||||
| Total Assets | 10.5 | 14.8 | 18.1 | 12.6 | |||||||||||||
| Account Payables | 0.3 | 0.7 | 0.1 | - | |||||||||||||
| Short Term Debt | - | - | 0.1 | - | |||||||||||||
| Deferred Revenue | - | 1.5 | 0.6 | - | |||||||||||||
| Other Current Liabilities | 4.2 | 0.9 | 3.4 | 2.8 | |||||||||||||
| Total Current Liabilities | 5.6 | 5.0 | 6.1 | 2.8 | |||||||||||||
| Long Term Debt | - | - | - | - | |||||||||||||
| Other Non-Current Liabilities | - | 1.3 | 0.6 | 0.3 | |||||||||||||
| Total Non-Current Liabilities | 0.3 | 1.4 | 0.6 | 0.3 | |||||||||||||
| Total Liabilities | 5.9 | 6.5 | 6.8 | 3.1 | |||||||||||||
| Common Stock | 1.2 | 6.7 | 14.1 | 14.2 | |||||||||||||
| Retained Earnings | -144.8 | -150.4 | -102.6 | -104.0 | |||||||||||||
| Total Stockholders Equity | 4.7 | 8.3 | 11.4 | 9.6 | |||||||||||||
| Total Liabilities and Equity | 10.5 | 14.8 | 18.1 | 12.6 | |||||||||||||